Stockreport

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF Positive CHMP opinion is based on pivotal Phase 3 PROTECT Study results European Commission decision is expected in Q2 2024 SAN DIEGO, Feb. 23, 2024 (GLOBE NEWSWIRE [Read more]